![\"\"](\"https:\/\/www.wdwire.com\/wp-content\/uploads\/2026\/06\/image-39.png\")
<\/p>\r\n
1. Company Overview & Core Technology<\/strong><\/p>\r\n <\/p>\r\n Company Background<\/strong><\/p>\r\n <\/p>\r\n CytoMed is a clinical-stage biotech spin-off from ASTAR, Singapore’s national scientific research agency. The company focuses on developing affordable cancer therapy using patented allogeneic Gamma Delta T Cells derived from healthy donors.<\/p>\r\n <\/p>\r\n Mission<\/strong><\/p>\r\n <\/p>\r\n The company aims to address the major limitations of existing cell therapies such as CAR-T, including high treatment costs and lengthy manufacturing timelines. By using blood from healthy donors to manufacture “off-the-shelf” immune cells, the company aims to reduce production costs and enable global distribution.<\/p>\r\n <\/p>\r\n Technological Advantages<\/strong><\/p>\r\n <\/p>\r\n Safety<\/strong><\/p>\r\n <\/p>\r\n Gamma Delta T Cells have a lower risk of causing Graft-versus-Host Disease (GVHD), making them suitable for allogeneic transplantation.<\/p>\r\n <\/p>\r\n Versatility<\/strong><\/p>\r\n <\/p>\r\n The cells express CARs (Chimeric Antigen Receptors) targeting NKG2D ligands, enabling recognition of multiple cancer types that express stress-related molecules, including Solid tumors & Hematological malignancies.<\/p>\r\n <\/p>\r\n 2. Clinical Trial Progress<\/strong><\/p>\r\n <\/p>\r\n Singapore ANGELICA Trial<\/strong><\/p>\r\n <\/p>\r\n Nature of the Trial<\/strong><\/p>\r\n <\/p>\r\n Ongoing first-in-human clinical trial targeting patients with:<\/p>\r\n <\/p>\r\n <\/p>\r\n Progress<\/strong><\/p>\r\n <\/p>\r\n The trial comprised 12 patients in total, and treatment has been completed for half of the participants (6 patients).<\/p>\r\n <\/p>\r\n Objective<\/strong><\/p>\r\n <\/p>\r\n To complete the Phase 1 clinical trial and evaluate before embarking on Phase 2 by next year 2027:<\/p>\r\n <\/p>\r\n <\/p>\r\n Malaysia Clinical Trial<\/strong><\/p>\r\n <\/p>\r\n Strategy<\/strong><\/p>\r\n <\/p>\r\n CytoMed plans to launch a first-in-human clinical trial for the unmodified version of the therapy, which is expected to be significantly less expensive than the CAR-T version.<\/p>\r\n <\/p>\r\n Collaboration<\/strong><\/p>\r\n <\/p>\r\n The company is collaborating with Universiti Malaya Hospital and is preparing to submit trial documentation to regulators and start by this year 2026.<\/p>\r\n <\/p>\r\n 3. Strategic Expansion & Acquisitions<\/strong><\/p>\r\n <\/p>\r\n Acquisition of TC BioPharm (UK)<\/strong><\/p>\r\n <\/p>\r\n Through this acquisition, CytoMed obtained feeder-free manufacturing technology, solving logistical challenges associated with cross-border transportation of specialized feeder cells and strengthening its cancer therapy platform.<\/p>\r\n <\/p>\r\n Acquisition of Longevity Bank (Malaysia)<\/strong><\/p>\r\n <\/p>\r\n Background<\/strong><\/p>\r\n <\/p>\r\n In mid-2024, CytoMed acquired a Malaysian cord blood bank that had entered liquidation due to the impact of the pandemic. The bank had approximately 12,000 customers.<\/p>\r\n <\/p>\r\n Strategic Purpose<\/strong><\/p>\r\n <\/p>\r\n The acquisition provides access to cord blood resources for the development of Natural Killer (NK) Cell therapies from pristine cord blood.<\/p>\r\n <\/p>\r\n NK cells have potential applications in:<\/p>\r\n <\/p>\r\n <\/p>\r\n This acquisition also broadens the company’s therapeutic pipeline.<\/p>\r\n <\/p>\r\n 4. Global Market Strategy: Focus on China & India<\/strong><\/p>\r\n <\/p>\r\n China (Key Strategic Focus)<\/strong><\/p>\r\n <\/p>\r\n Policy Opportunity<\/strong><\/p>\r\n <\/p>\r\n CytoMed is closely monitoring China’s “Directive 818,” which allows hospitals conducting investigator-initiated trials (IITs) to charge patients, thereby helping subsidize biotechnology companies’ R&D and manufacturing costs.<\/p>\r\n <\/p>\r\n Competitive Advantage<\/strong><\/p>\r\n <\/p>\r\n Compared with the capital-intensive “cash-burning” model commonly seen in Western biotech companies, the Chinese model is viewed as more sustainable.<\/p>\r\n <\/p>\r\n China’s Government-backed biotech parks, Pragmatic regulatory policies & Strong venture capital ecosystem have made the country highly attractive for biotechnology development.<\/p>\r\n <\/p>\r\n Market Potential<\/strong><\/p>\r\n <\/p>\r\n China has a massive cancer patient population and regulatory flexibility for compassionate-use style commercialization making it a critical strategic market for CytoMed.<\/p>\r\n <\/p>\r\n India<\/strong><\/p>\r\n <\/p>\r\n As one of the world’s two largest population centres, India is also a major target market for the company.<\/p>\r\n <\/p>\r\n United States<\/strong><\/p>\r\n <\/p>\r\n Although CytoMed collaborates with MD Anderson Cancer Center — where animal studies showed effectiveness against AML — the company currently does not prioritize the U.S. market due to the long time and extremely high cost of clinical trials.<\/p>\r\n <\/p>\r\n 5. Financial Position & Industry Perspectives<\/strong><\/p>\r\n <\/p>\r\n Financial Status<\/strong><\/p>\r\n <\/p>\r\n <\/p>\r\n View on the “Biotech Winter”<\/strong><\/p>\r\n <\/p>\r\n The Chairman believes the biotech industry is currently experiencing a “winter” caused by:<\/p>\r\n <\/p>\r\n <\/p>\r\n The company also faces:<\/p>\r\n <\/p>\r\n <\/p>\r\n Strategic Pivot<\/strong><\/p>\r\n <\/p>\r\n To survive the difficult funding environment, CytoMed is shifting toward closer collaboration with hospitals to provide treatments for “no-option” patients.<\/p>\r\n <\/p>\r\n The company benefits from low cost infrastructure in Southeast Asia and aims to:<\/p>\r\n <\/p>\r\n <\/p>\r\n 6. Regulatory Advocacy<\/strong><\/p>\r\n <\/p>\r\n Compassionate Use<\/strong><\/p>\r\n <\/p>\r\n CytoMed advocates for regulators to adopt a more flexible approach for terminal patients who have exhausted all available treatment options, allowing access to new cell therapies.<\/p>\r\n <\/p>\r\n East-West Differences<\/strong><\/p>\r\n <\/p>\r\n The Chairman noted that Eastern societies, particularly in Southeast Asia, generally have less aggressive litigation cultures compared with Western countries such as the United States.<\/p>\r\n <\/p>\r\n This creates a more favourable environment for Compassionate Use programs, allowing terminal patients to try innovative therapies when conventional options have failed.<\/p>\r\n <\/p>\r\n Conclusion<\/strong><\/p>\r\n <\/p>\r\n The interview highlights CytoMed’s unique “low-cost survival strategy” within the highly expensive biotechnology sector.<\/p>\r\n <\/p>\r\n By leveraging:<\/p>\r\n <\/p>\r\n <\/p>\r\n the company has identified a pragmatic commercialization pathway during the ongoing biotech capital winter.<\/p>\r\n <\/p>\r\n CytoMed’s approach demonstrates not only technological ambition, but also strong strategic insight into the evolving global biotechnology landscape.<\/p>\r\n <\/p>\r\n <\/p> Media Contact<\/span> In February 2026, The Wall Street Transcript published an exclusive interview with CytoMed Therapeutics Ltd (NASDAQ: GDTC) Chairman Choo Chee Kong. The interview covered the company’s technological approach, clinical trial<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/537244"}],"collection":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/comments?post=537244"}],"version-history":[{"count":0,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/537244\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/media?parent=537244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/categories?post=537244"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/tags?post=537244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
Company Name:<\/strong> CytoMed Therapeutics Ltd
Contact Person:<\/strong> Ms Evelyn
Email:<\/strong> Send Email<\/a>
Country:<\/strong> Singapore
Website:<\/strong> https:\/\/www.cytomed.sg\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"